EP Patent

EP0786264A2 — Devices for treating pulmonary vasoconstriction and asthma

Assigned to General Hospital Corp · Expires 1997-07-30 · 29y expired

What this patent protects

A method for treating or preventing bronchoconstriction or reversible pulmonary vasoconstriction in a mammal, which method includes causing the mammal to inhale a therapeutically-effective concentration of gaseous nitric oxide (1,10) or a therapeutically-effective amount of a nit…

USPTO Abstract

A method for treating or preventing bronchoconstriction or reversible pulmonary vasoconstriction in a mammal, which method includes causing the mammal to inhale a therapeutically-effective concentration of gaseous nitric oxide (1,10) or a therapeutically-effective amount of a nitric oxide-releasing compound (106), and an inhaler device (102) containing nitric oxide gas and/or a nitric oxide-releasing compound.

Drugs covered by this patent

Patent Metadata

Patent number
EP0786264A2
Jurisdiction
EP
Classification
—
Expires
1997-07-30
Drug substance claim
No
Drug product claim
No
Assignee
General Hospital Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.